IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
NAZARE, et al.

Examiner:

Art Unit: 1614

Application No.: **10/728,339**

Filed: **December 4, 2003**

Title: **IMIDAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 14, 2005
Date of Deposit

Signature

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or

☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The publication by KEMPTER, et al., Darstellung Von Heterocyclisch Substituierten Imidazolen Und Imidazo [2.1-b] Thiazolen, J. Prakt. Chem., 1971, 977-985 discloses:
The preparation of substituted imidazole and imidazo[2.1-b]thiazolene derivatives out of alpha-halogenketones and amidines. The general process described can be used for the preparation of the imidazole ring system.

Respectfully submitted,

Joseph Rossi, Reg. No. 31,403
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-**3410**
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0085 US NP

Please type a plus sign (+) inside this box → ☑

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known	
Application Number	10/728,339
Filing Date	12-04-2003
First Named Inventor	NAZARÉ
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	DEAV2002/0085 - US - NP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4,395,547		RAGHU, et al.	07-26-1983	
		6,020,357		PINTO, et al.	02-01-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		EP	0987274		SAFAR, et al.	03-22-2000		
		WO	01/32628		PINTO, Donald, J., P.	05-10-2001		
		WO	02/00651		QUAN, et al.	01-03-2002		
		WO	92/06711		SOULE, et al.	04-30-1992		
		WO	95/29189		AL-OBEIDI, et al.	11-02-1995		
		WO	96/12800		BERKNER, et al.	05-02-1996		
		WO	97/47651		PETERSEN, et al.	12-18-1997		
		WO	01/07436		EWING, et al.	02-01-2001		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☑

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 7

Complete if Known	
Application Number	10/728,339
Filing Date	12-04-2003
First Named Inventor	NAZARÉ
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	DEAV2002/0085 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		ABAD, et al., N-Multilabeled Adenine and Guanine Nucleosides. Syntheses Of [1,3,NH2-15N3]- and [2-13C-1,3,NH2-15N3]-Labeled Adenosine, Guanosine, 2'-Deoxyadenosine, and 2'-Deoxyguanosine, J. Org. Chem. 1999, 64, 6575-6582	
		ABARBRI, et al., Preparation Of New Polyfunctional Magnesiated Heterocycles Using A Chlorine-, Bromine-, or Iodine -Magnesium Exchange, J. Org. Chem. 2000, 65, 4618-4634	
		ALLEN, et al., Self-Assembled Helices From 2,2'-Biimidazoles, Chem. Eur. J. 2001, 7(3), 721-729	
		ANTHONY, et al., Design And In Vivo Analysis Of Potent Non-Thiol Inhibitors Of Farnesyl Protein Transferase, J. Med. Chem. 1999, 42, 3356-3368	
		ADANG, et al., A New Generation Of Orally Active Antithrombotics: Comparing Strategies In The GPIIb/IIIa, thrombin and Factor Xa areas, Drugs of the Future 2000, 25,369-383	
		BALDWIN, et al., Beta1-Selective Adrenoceptor Antagonists: Examples Of The 2-[4-[3-(Substituted Amino)-2-Hydroxypropoxyl] phenyl] Imidazole Class. 2, J. Med. Chem. 1986, 29, 1065-1080	
		BALDWIN, et al., 4-Trifluoromethylimidazoles And 5-(4-Pyridyl)-1,2,4-triazoles, New Classes Of Xanthine Oxidase Inhibitors, J. Med. Chem., 1975, 18(9), 895-900	
		BALDWIN, et al., Beta-Adrenergic Blocking Agents With Acute Antihypertensive Activity, J. Med. Chem., 1979, 22(6), 687-694	
		BRACKEEN, et al., An Efficient And Mild Synthesis Of Highly Substituted Imidazoles, Tetrahedron Lett. 1994, 1635-1638	
		BRESLOW, et al., Synthesis Of Some Polyimidazole Ligands Related To Zinc Enzymes, J. Am. Chem. Soc. 1983, 105, 5337-5342	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☑

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 7

Complete if Known	
Application Number	10/728,339
Filing Date	12-04-2003
First Named Inventor	NAZARÉ
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	DEAV2002/0085 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		BUNDGAARD, et al., Novel Chemical Approaches in Prodrug Design, Drugs Of The Future, 16 (1991) 443-458	
		CHAN, et al., New N- and O-Arylations With Phenylboronic Acids And Cupric Acetate, Tetrahedron Letters 39 (1998) 2933-2936	
		CHENG Yung-Chi et al., Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which causes 50 per cent Inhibition (I 50) of an Enzymatic Reaction, Biochem. Pharmacol., 1973, Vol. 22, pgs 3099-3108	
		COLLMAN, et al., Catalytic Activities of Cu(II) Complexes with Nitrogen-Chelating Bidentate Ligands in the Coupling of Imidazoles with Arylboronic Acids, J. Org. Chem.; 66; 2001; pp.7892-7897.	
		COZZI, et al., Ethyl 2-{[5,6-Dihydro-7-(1H-Imidazol-1-YL)2-Naphthalenyl] Oxy}-2-Methylpropanoate As A New Potent Oxyisobutyrate Hypolipidaemic With Unusual Features, Farmaco (1987) 42, 205-218	
		FLEISHER, et al., Improved Oral Drug Delivery: Solubility Limitations Overcome By The Use Of Prodrugs, Advanced Drug Delivery Reviews 19 (1996) 115-130	
		HARTWIG John F et al., Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand, J. Org. Chem., 1999, Vol. 64, pgs. 5575-5580	
		HARTWIG, John, Transition Metal Catalyzed Synthesis of Arylamines and Aryl Ethers from Aryl Halides and Triflates: Scope and Mechanism, Angew. Chem. 1998, 37, 2046-2067	
		HEINDEL, et al., Imidazole Carboxylates By A Claisen-Type Rearrangement Of Amidoxime-Propiolate Adducts, Tetrahedron Letters No. 1971, No. 18, pp. 1439-1440	
		JIMONET, et al., Bioisosteres Of 9-Carboxymethyl-4-Oxo-Imidazol[1,2-a]Indeno-[1,2-e]Pyrazin-2-Carboxylic Acid Derivatives. Progress Towards Selective, Potent In Vivo AMPA Antagonists With Longer Durations Of Action, Bioorganic & Medicinal Chemisty Letters 2001, 11, 127-132	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☑

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 7

Complete if Known	
Application Number	10/728,339
Filing Date	12-04-2003
First Named Inventor	NAZARÉ
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	DEAV2002/0085 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		JUDD, et al., Bromobenzofuran-Based Non-Peptide Antagonists Of Angiotensin II: GR13895, A Potent Antihypertensive Agent With High Oral Bioavailability, J. Med. Chem. 1994, 37, 3108-3120	
		KANG, et al., Copper-Catalyzed N-Arylation Of Aryl Iodides With Benzamides Or Nitrogen Heterocycles In The Presence Of Ethylenediamine, Synlett 2002, 3, 427-430	
		KAWASAKI, et al., Total Synthesis Of Nortopsentins A-D, Marine Alkaloids, Chem. Pharm. Bull. 44(10) 1831-1839	
		KEMPTER, et al., Darstellung Von Heterocyclisch Substituierten Imidazolen Und Imidazo [2.1-b] Thiazolen, J. Prakt. Chem., 1971, 977-985	
		KIM, et al, Preparation Of N(pi)-Alkyl- Histamine And Histidine Derivatives Through Efficient Alkylation Followed by Deprotection Using Activated Silica Gel, Tetrahedron Lett., 2000, 41, 10031-10034	
		KIMBONGUILA, et al. , On The Allyl Protection Of The Imidazole Ring Of Histidine, Tetrahedron, 1997, 53(37), 12525-12538	
		KLAPARS, et al., A General And Efficient Copper Catalyst For The Amidation Of Aryl Halides And the N-Arylation of Nitrogen Heterocycles, J. Am. Chem. Soc. 2001, 123, 7727-7729	
		KWONG, et al., Copper-Catalyzed Coupling Of Alkylamines And Aryl Iodides: An Efficient System Even In An Air Atmosphere, Organic Lett. 2002, 4 (4), 581-584	
		LAM, et al., New Aryl/Heteroaryl C-N Bond Cross-coupling Reactions Via Arylboronic Acid/Cupric Acetate Arylation, Tetrahedron Letters 39 (1998) 2941-2944	
		MANN Grace et al., Palladium-Catalyzed C-N(sp 2) Bond Formation: N-Arylation of Aromatic and Unsaturated Nitrogen and the Reductive Elimination Chemistry of Palladium Azolyl and Methyleneamido Complexes, J. Am. Chem. Soc., 1998, Vol. 120, pgs. 827-828	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☑

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 7

Complete if Known	
Application Number	10/728,339
Filing Date	12-04-2003
First Named Inventor	NAZARÉ
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	DEAV2002/0085 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		MATTHEWS, et al., Synthesis And Cardiotonic Activity Of Novel Biimidazoles, J. Med. Chem., 1990, 317-327	
		MEDERSKI Werner W K R et al., N-Aryl Heterocycles via Coupling Reactions with Arylboronic Acids, Tetrahedron, 1999, Vol. 55, pgs. 12757-12770	
		NICHOLS, et al., 1-(2,5-Dimethoxy-4-(Trifluoromethyl) Phenyl)-2-Aminopropane: A Potent Serotonin 5-HT2A/2C Agonist, J. Med. Chem. 1994,37, 4336-4351	
		O'CONNELL, et al., Convenient Synthesis Of Methyl 1-Methyl-2,4-dibromo-5-imidazolecarboxylate, Synthesis 1988, 767-771	
		OHMORI, et al., Novel AMPA Receptor Antagonists: Synthesis and Structure-Activity Relationships of 1-Hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)-quinoxalinedione and Related Compounds, J. Med. Chem.; 39; 1996; pp.3971-3979.	
		OLD David W et al., Efficient Palladium-Catalyzed N-Arylation of Indoles, Organic Letters, 2000, Vol. 2, No. 10, pgs. 1403-1406	
		OSTREM James A et al., Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors via Combinatorial Chemistry, Biochemistry, 1998, Vol. 37, pgs. 1053-1059	
		PAUL, et al., Imidazo[1,5-d][1,2,4]Triazines as Potential Antiasthma Agents, J. Med. Chem. 1985, 28, 1704-1716	
		PIERCE, et al., Practical Synthesis And Regioselective Alkylation Of Methyl 4(5)-Pentafluoroethyl)-2-Propylimidazole-5(4)-Carboxylate To Give DuP 532, A Potent Angiotensin II Antagonist, J. Org. Chem. 1993, 58, 4642-4645	
		QING, et al., First Synthesis Of Ortho-Trifluoromethylated Aryl Triflates, J. Chem Soc. Perkin Trans. I, 1997, 20, 3053-3057	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☑

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 7

Complete if Known	
Application Number	10/728,339
Filing Date	12-04-2003
First Named Inventor	NAZARÉ
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	DEAV2002/0085 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		SAKAMOTO, et al., Palladium-Catalyzed Cyanation Of Aryl and Heteroaryl Iodides With Copper (I) Cyanide, J. Chem. Soc. Perkin Trans I, 1999, 2323-2326	
		SEGEL Irwin H, Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, Enzyme Kinetics, 1975, John Wiley & Sons, New York, pgs. 100-125	
		SHI, et al., A Practical Synthesis Of 2-Butyl-4-(5)-Chloro-5(4)-Hydroxymethyl-1H-Imidazole, Synthetic Communications, 1993, 23(18), 2623-2630	
		SHILCRAT, et al., A New Regioselective Synthesis Of 1,2,5-Trisubstituted 1H-Imidazoles And Its Application To The Development Of Eprosartan, J. Org. Chem. 1997, 62, 8449-8454	
		SU, et al., Methyl Chlorodifluoro Acetate A Convenient Trifluoromethylating Agent, Tetrahedron Lett. 1991, 32 (52), 7689-7690	
		TOKMAKOV Gennadii P et al., Rearrangement of 1-Arylindoles to 5H-Dibenz[b,f]azepines, Tetrahedron, 1995, Vol. 51, No. 7, pgs. 2091-2098	
		UMEMOTO, et al., Power And Structure-Variable Fluorinating Agents. The N-Fluoropyridinium Salt System, J. Am. Chem. Soc. 1990, 112, 8563-8575	
		UNANGST Paul C et al., Synthesis of Novel 1-Phenyl-1H-indole-2-carboxylic Acids. I. Utilization of Ullmann and Dieckmann Reactions for the Preparation of 3-Hydroxy, 3-Alkoxy, and 3-Alkyl Derivatives, J. Heterocyclic Chem., 1987, Vol. 24, pgs. 811-815	
		URATA, et al., A Novel And Convenient Method For Trifluoromethylation Of Organic Halides Using CF3SiR'3/KF/Cu(I) System, Tetrahedron Lett. 1991, 32(1), 91-94	
		VERONESE, et al., One-Pot Synthesis of 2-Vinylimidazole Derivatives By Reaction Of Alpha-Hydroxyimino-Beta Dicarbonyl Compounds With Allylamine, Synthesis 1985, 300-302	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☑

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 7

Complete if Known	
Application Number	10/728,339
Filing Date	12-04-2003
First Named Inventor	NAZARÉ
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	DEAV2002/0085 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		VERONESE, et al., Syntheses Of 2-Arylimidazole Derivatives Through Annelations Employing Benzylamines, J. Heterocyclic Chem., 17, 1723-1725	
		WEGNER, et al., Imidazole Aus Aldehyden, 1,2-Diketonen Und Fluessigem Ammoniak, Arch. Pharm, 1974, 492-495 English Abstract on Page 492.	
		WOLFE, et al., Simple, Efficient Catalyst System For The Palladium-Catalyzed Amination Of Aryl Chlorides, Bromides, and Triflates, J. Org. Chem. 2000, 65, 1158-1174	
		YAMADA, et al., 2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent[d]imidazoles As A Novel Class Of Gastric H+/K+-ATPase Inhibitors, J. Med. Chem. 1996, 39, 596-604	
		YAMANAKA, et al., Syntheses Of Heteroaromatic Carboxylic Acids Closely Related To Fusaic Acid, Chem. Pharm. Bull. 1983 31(12) 4549-4553	
		YANG, et al., Palladium-Catalyzed Amination Of Aryl Halides And Sulfonates, J. Organomet. Chem. 1999, 576, 125	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.